1 UBR1 Promotes Sex-Dependent ACE2 Ubiquitination in Hypertension

*Mona Elgazzaz^{1,2,5,6}, *Navya Lakkappa^{2,5}, Clara Berdasco^{2,5}, Uma Priya Mohan^{1,5},
 Anna Nuzzo,¹ Luke Restivo¹, Alexa Martinez,¹ Amy Scarborough,¹ Jessie J. Guidry²,

4 Srinivas Sriramula^{2,7}, Jiaxi Xu^{2,8}, Hisham Daoud⁹, Michelle A. Mendiola Plá¹⁰, Dawn E.

- 5 Bowles¹⁰, Andreas M. Beyer¹¹, Franck Mauvais-Jarvis^{5,12}, Xinping Yue^{1,2}, Catalin M.
- 6 Filipeanu¹³ and [#]Eric Lazartigues^{1,2,3,4,5}
- 7
- ⁸ ¹Cardiovascular Center of Excellence, Departments of ²Pharmacology & Experimental
- 9 Therapeutics and ³Medicine, and ⁴Neuroscience Center of Excellence, Louisiana State
- 10 University Health Sciences Center, New Orleans, LA 70112, USA;
- ⁵Southeast Louisiana Veterans Health Care System, New Orleans, LA 70119, USA;
- ¹² ⁶Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez ¹³ Canal University, Ismailia, 41522, Egypt;
- ¹⁴ ⁷Department of Pharmacology and Toxicology, Brody School of Medicine at East ¹⁵ Carolina University, Greenville, NC 27834, USA;
- ¹⁶ ⁸Department of Physiology and Pathophysiology, Xi'an Jiaotong University, School of
- 17 Medicine, Xi'an, 710061, China;
- ⁹School of Computer and Cyber Sciences, Augusta University, Augusta, GA 30901,
 USA
- ¹⁰Division of Surgical Sciences, Department of Surgery, Duke University, Durham, NC
 27710, USA;
- ¹¹Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA;
- ¹²Deming Department of Medicine, Tulane University, New Orleans, LA 70112, USA;
- ¹³Department of Pharmacology, Howard University, Washington, DC 20059, USA.
- 25
- ²⁶ *Both authors contributed equally.
- 27
- 28 Running title: ACE2 ubiquitination in hypertension
- 29

30 Number of words: 6270

- 31
- 32
- ³³ [#]Correspondence to:
- Dr. Eric Lazartigues, PhD; Louisiana State University Health, School of Medicine, Cardiovascular Center of Excellence, 533 Bolivar Street, New Orleans, LA 70112. E-
- 36 mail: <u>elazar@lsuhsc.edu</u>
- 37

38 Abstract

39

Background: Angiotensin (Ang)-II impairs the function of the antihypertensive enzyme ACE2 by promoting its internalization, ubiquitination and degradation thus contributing to hypertension. However, few ACE2 ubiquitination partners have been identified and their role in hypertension remains unknown.

Methods: Proteomics and bioinformatic analysis were used to identify ACE2
ubiquitination partners in the brain, heart, and kidney from Ang-II-infused C57BL6/J
mice from both sexes and validated the interaction between UBR1 and ACE2 in cells.
Central and peripheral UBR1 knockdown was then performed in male mice to
investigate its role in the maintenance of hypertension.

Results: Proteomics analysis from hypothalamus identified UBR1 as a potential E3 49 ligase promoting ACE2 ubiquitination. Enhanced UBR1 expression, associated with 50 ACE2 reduction, was confirmed in various tissues from hypertensive male mice and 51 52 human samples. Treatment of endothelial and smooth muscle cells with testosterone, but not 17β-estradiol, confirmed a sex-specific regulation of UBR1. In vivo silencing of 53 UBR1 using chronic administration of small interference RNA resulted in the restoration 54 of ACE2 levels in hypertensive males. A transient decrease in blood pressure following 55 56 intracerebroventricular, but not systemic, infusion was also observed. Interestingly, 57 UBR1 knockdown increased the brain activation of Nedd4-2, an E3 ligase promoting 58 ACE2 ubiquitination and reduced expression of SGK1, the kinase inactivating Nedd4-2.

59 Conclusions: These data demonstrate that UBR1 is a novel ubiquitin ligase targeting 60 ACE2 in hypertension. UBR1 and Nedd4-2 E3 ligases appear to work synergistically to 61 ubiquitinate ACE2. Targeting of these ubiquitin ligases may represent a novel strategy 62 to restore ACE2 compensatory activity in hypertension.

63

64 **Keywords:** ACE2, renin-angiotensin system, hypertension, ubiquitin, sex differences.

66 Nonstandard Abbreviation and Acronyms:

- 67
- 68 ACE2 Angiotensin Converting Enzyme 2
- 69 Ang-II Angiotensin II
- 70 Ang-(1-7) Angiotensin (1-7)
- 71 ANOVA Analysis of variance
- 72 AT₁R Ang-II type 1 receptor
- 73 **BP** Blood pressure
- 74 **DHT** dihydrotestosterone
- 75 DBDi androgen receptor (AR) DNA-binding domain inhibitor
- 76 E1 Ubiquitin-activating enzymes
- 77 E2 Ubiquitin-conjugating enzymes
- 78 E3 Ubiquitin protein ligases
- 79 **ENaC** Kidney epithelial Na⁺ channels
- 80 **HAEC** Human aortic endothelial cells
- 81 LC-MS Liquid chromatography–mass spectrometry
- 82 MAP Mean arterial pressure
- 83 MDM2 Murine double minute 2
- 84 MPP Methylpiperidinopyrazole
- 85 Nedd4-2 Neural Precursor Cell Expressed Developmentally Down-Regulated Protein 4
- 86 **PHTPP** 4-[2-PHENYL-5,7-BIS(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDIN-3-
- 87 YL]PHENOL
- 88 **RAS** Renin-angiotensin system
- 89 Skp2 S-Phase Kinase Associated Protein 2
- 90 siRNA Small interfering RNA
- 91 **SMC** Smooth muscle cell
- 92 SGK1 Serum/Glucocorticoid-Regulated Kinase 1
- 93 UBR1 Ubiquitin Protein Ligase E3 Component N-Recognin

94 Introduction

Angiotensin Converting Enzyme 2 (ACE2) is an important compensatory enzyme of the 95 renin-angiotensin system (RAS), converting the potent vasoconstrictor Angiotensin 96 (Ang)-II to the vasodilatory peptide Ang-(1-7).¹ We previously reported that ACE2 is the 97 target of Ang-II-induced internalization and degradation via the Ang-II type 1 receptor 98 (AT₁R), a process involving ubiquitination.²⁻⁴ Ubiquitination is a three-step enzymatic 99 100 process involving ubiquitin-activating enzymes (E1) binding to ubiquitin using a molecule of ATP, followed by ubiquitin-conjugating enzymes (E2), carrying the ubiquitin 101 protein and conjugating with ubiguitin protein ligases (E3). E3 recognizes the protein to 102 be labeled and catalyzes the transfer of ubiquitin to the target protein. The pathway 103 104 continues until the target protein has a desired chain of poly-ubiquitins which is then subjected to lysosomal/proteasomal degradation.^{5,6} Ubiquitination plays an important 105 role in the development of hypertension.⁷ Indeed, Nedd4-2, that we recently implicated 106 in ACE2 ubiquitination.³ is a well-known E3 ligase controlling cell surface expression of 107 kidney epithelial Na⁺ channels (ENaC) via ubiquitin-mediated endocytosis and 108 lysosomal degradation.⁷ Mutations of ENaC have also been reported to interfere with 109 110 ubiquitination by Nedd4-2, resulting in Liddle syndrome, a monogenic hypertensive condition.^{8,9} Expression of Nedd4-2 was enhanced in the hypothalamus of mice and 111 endothelial cell cultures following Ang-II treatment and associated with a decrease in 112 ACE2 while knockdown of Nedd4-2 restored ACE2 expression.³ Importantly, prevention 113 of ACE2 ubiquitination resulted in the maintenance of a GABAergic inhibitory input to 114 presympathetic neurons in the hypothalamus and a reduction of hypertension. 115

While our group was first to report that Ang-II treatment induces ACE2 internalization 116 and ubiquitination through an AT₁R-dependent mechanism,^{2,4} very few reports have 117 focused on ACE2 ubiquitination partners.¹ Murine double minute 2 (MDM2) E3 ligase 118 was the first enzyme shown to promote ACE2 ubiquitination, possibly contributing to the 119 development of pulmonary arterial hypertension.¹⁰ Another E3 ligase, S-Phase Kinase 120 Associated Protein 2 (Skp2), was reported to be upregulated by cigarette smoke 121 carcinogens, leading to ACE2 ubiquitination in lung epithelial cells.^{11,12} However, 122 despite more than two decades of research establishing ACE2 as a critical player for 123 cardiovascular regulation, and several recent studies related to SARS-CoV-2 infection,¹ 124

there is limited knowledge about the enzymes and mechanisms controlling ACE2
 ubiquitination and the overall implications for cardiovascular regulation.

127 Incertitude also persists regarding sex differences in ACE2 expression and activity. Early work in rodents showed that ACE2 expression^{13,14} and activity¹⁵ are tissue-128 specific, higher in male kidneys and under the control of estrogens, while others 129 reported no sex difference. Estrogens and testosterone are well known to affect the 130 expression and activity of RAS components, contributing to sex differences in 131 cardiovascular outcomes.^{16,17} Estrogens have also been reported to upregulate the 132 protective Ang-(1-7)/ACE2/Mas1R/AT₂R,¹⁸ notably by increasing ACE2 gene 133 expression.¹⁹ In humans, studies have shown differential smooth muscle cells 134 expression of ACE2 in the airways of males and females. Clinical studies also reported 135 that higher levels of circulating soluble ACE2, previously shown by us to be a marker of 136 disease.^{20,21} were associated with the male sex, cardiovascular disease, diabetes, and 137 age; although increased ACE2 shedding does not imply sex differences at baseline.^{22,23} 138 Hence, sex differences in ACE2 expression are still poorly understood and the effect of 139 140 sex hormones on ACE2 ubiguitination in normotensive and hypertensive conditions has not been investigated. 141

In the current study, we identified UBR1, an E3 ligase part of the N-end rule proteolytic pathway of the ubiquitin system, as a sex-dependent regulator of ACE2 expression in hypertension. We further report that the knockdown of UBR1 prevented ACE2 degradation, which supports its role in ACE2 ubiquitination and could lay the foundation for new therapeutic strategies to prevent the loss of ACE2 compensatory activity in hypertension.

148

149 Methods

The authors declare that all supporting data are available within the article and in the Data Supplement. A detailed Methods section is available in the Online Data Supplement.

153

Experiments were conducted in adult C57BL6/J mice (8–12 weeks old, 20-25 g; Jackson Laboratory, Bar Harbor, ME) from both sexes. Mice were housed in a

temperature- (~25 °C) and humidity-controlled facility under a 12-hour dark/light cycle, 156 fed standard mouse chow (Envigo, iOS Teklab Extruded Rodent Diet 2019S, 157 158 Huntingdon, UK) and water ad libitum. All procedures conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were 159 160 approved by the Louisiana State University Health Sciences Center (#3540), and the Southeast Veterans Healthcare System (#620) Institutional Animal Care and Use 161 162 Committees. Cardiac samples were obtained from The Medical College of Wisconsin (IRB # PRO00010828) and Duke University (IRB # PRO00005621). 163

164

165 **Results**

166 UBR1 Ubiquitin ligase is predicted to interact with ACE2 in hypertension.

To identify ACE2 ubiquitination partners in hypertension, a proteomic analysis was 167 initially performed as reported previously.²⁴ Following 4 weeks of Ang-II infusion, the 168 hypothalamus was isolated and underwent proteomic analysis using Liquid 169 chromatography-mass spectrometry (LC-MS) with a focus on ubiquitination-related 170 proteins (Figure 1A). Based on abundance score, our data show an upregulation of the 171 E3 ligase UBR1 in Ang-II- induced hypertension in wild type mice hypothalamus (Figure 172 1B and Table S1). To investigate whether ACE2 could be a potential target for UBR1, 173 174 we used bioinformatic tools to evaluate the interaction between ACE2 and UBR1. Using the Biological General Repository for Interaction Datasets (BioGRID) to explore curated 175 interactions between ACE2 and ubiquitin ligases,²⁵ multiple ubiquitin ligases were 176 shown to interact with ACE2 in humans, among which is UBR1 (Figure 1C). 177

ACE2 ubiquitination was further investigated in hypertension induced by Ang-II infusion in both male and female mice. There was no significant blood pressure (BP) or heart rate difference between male and female mice before Ang-II treatment (Figure 1D and S1). Ang-II treatment resulted in a significant rise in BP that plateaued by the 4th week of infusion. Hypertension was significantly higher in males than in females in both active and resting phases (Figure 1D).

184

185 Sex hormones regulate the expression of UBR1 and ACE2.

186 Protein expression for UBR1 and ACE2 was assessed in the mouse brain (Figure 2A). heart (Figure 2B) and kidneys (Figure 2C). We observed that male mice treated with 187 188 Ang-II showed a 2 to 3-fold increase in UBR1 levels in those tissues. Although UBR1 expression trended to an increase in females, it only reached significance in males. 189 190 ACE2 protein expression was significantly higher in males, notably in the brain (Figure 2E), while similar in the kidney for both sexes (Figure 2G). Although these higher levels 191 192 were not significant in the mouse heart (Figure 2F), data from human left ventricles (Figure 2H) confirmed the elevated level in males. Ang-II treatment dramatically 193 reduced ACE2 expression, notably in the male brain (Figure 2E) with limited (Figure 2G) 194 or no impact (Figure 2E,F) in females. Together, these data suggest that Ang-II-induced 195 upregulation of UBR1 in males could contribute to the downregulation of ACE2. To 196 assess the clinical relevance of UBR1 in human hypertension, we evaluated left 197 ventricle cardiac samples from rejected donor hearts (Males: 47.5 ±2.5, Females: 43.8 198 ± 2.1 years old, n=6/group, Table S2) with or without hypertension. As observed in mice, 199 ACE2 expression was higher in male normotensive donors (Figure 2H) and decreased 200 with hypertension. UBR1 protein levels were strongly upregulated in hypertensive 201 donors (Figure 2D), regardless of sex, but were associated with a decrease in ACE2 202 protein in males only (Figure 2H). Together, these data confirm that UBR1 upregulation 203 and the concomitant ACE2 downregulation observed in our preclinical model is 204 205 recapitulated in hypertensive subjects.

206

207 UBR1 contributes to Ang-II-mediated ACE2 downregulation.

To assess causality between UBR1 upregulation and ACE2 downregulation, primary 208 209 human aortic endothelial cells (HAEC) were transfected with a UBR1 siRNA which led to a dose-dependent upregulation of ACE2 (Figure 3A). Pre-treatment with UBR1 210 211 siRNA produced a significant knockdown of UBR1 expression (***P<0.001), associated with a parallel increase in ACE2 levels (**P<0.01), demonstrating that UBR1 212 constitutively regulates ACE2 expression. As observed in mice (Figure 2), Ang-II 213 treatment of HAEC led to a significant upregulation of UBR1, associated with a 214 reduction of ACE2 protein levels (Figure 3B; ***P<0.001). Immunolabeling (Figure 3C) 215 showed that in baseline conditions ACE2 is expressed on the cell surface of HAEC 216

217 while UBR1 is located throughout the cell surface and cytoplasm. Upon treatment with Ang-II, ACE2 was internalized in the cytoplasm but also in the nucleus where it strongly 218 219 co-localized with UBR1. Importantly, silencing of UBR1 prevented not only prevented the Ang-II mediated upregulation of this E3 ligase but also resulted in an increase in 220 221 ACE2 levels (Figure 3B; ***P<0.001). These data suggest that UBR1 is critical for Ang-II-mediated downregulation of ACE2. Since UBR2 has been shown to functionally 222 223 overlap with UBR1, the possibility that UBR2 could also ubiquitinate ACE2 was further investigated. As suspected, transfection with UBR2 in HEK293T cells reduced ACE2 224 expression and activity (Figure S2 in data supplement) but this effect was independent 225 of Ang-II. Together, these data confirm that UBR1 is a newly identified mediator of 226 ACE2 ubiquitination. 227

228

229 Role of sex hormones in UBR1 expression

To further address the role of sex hormones on ACE2 ubiguitination by UBR1, we 230 expanded our experiments to HAEC and smooth muscle cells (SMC) to test for possible 231 cell specificity. Similar to the lack of UBR1 upregulation in female mice (Figure 2), 17β-232 estradiol treatment failed to increase UBR1 expression in HAEC (Figure 4A,B) or SMC 233 (Figure 4A,C), in the presence or absence of Ang-II. While 17β-estradiol did not affect 234 ACE2 expression (Figure 4A,E) in HAEC, blockade of either alpha or beta estrogen 235 236 receptors (using MPP and PHTPP, respectively) prevented the Ang-II mediated upregulation of UBR1 and concomitant downregulation of ACE2 (Figure 4A,B,D) in 237 HAEC, suggesting that 17β -estradiol might have a synergistic action with Ang-II on 238 UBR1 expression. Unlike 17β-estradiol, DHT alone increased UBR1 expression in 239 240 SMC, but not in HAEC (Figure 4A-C). In both cells, this was associated with reduced ACE2 expression independently of Ang-II (Figure 4A,D,E). While and rogen receptor 241 242 blocker flutamide was ineffective, likely due to incomplete prevention of DNA binding, these responses could be prevented by the androgen receptor DNA binding domain 243 244 inhibitor (DBDi). Together, these data show that male sex hormones appear to upregulate UBR1 and simultaneously reduce ACE2 in a cell specific manner while 17β-245 estradiol has no direct impact on UBR1. 246

247

248 UBR1 knockdown restores ACE2 levels in hypertensive mice.

Based on our observations that UBR1 is only upregulated in males, we proceeded to 249 250 investigate the role of UBR1 in ACE2 ubiquitination and hypertension. C57BI6/J males (12-week-old, n=5/group) were chronically infused with Ang-II for 4 weeks while treated 251 252 centrally or peripherally to achieve UBR1 knockdown (Figure 5A). UBR1 silencing following the establishment of hypertension had no immediate effect when administered 253 254 centrally but was associated with an increase in BP in the first week of treatment, when infused peripherally (Figure 5B). A transient reduction in BP occurred in the central 255 UBR1 siRNA group after 3 weeks of UBR1 knockdown (Figure 5B,C), most notably in 256 the resting phase of the nychthemeral cycle. In both peripheral and central UBR1 siRNA 257 groups, Ang-II-induced upregulation of UBR1 was blunted (Figure 6A), and this was 258 paralleled with a restoration of ACE2 protein levels in the hypothalamus (Figure 6B). 259 Interestingly, the Ang-II mediated upregulation of UBR1 was associated with an 260 increase in another E3 ligase expression, Nedd4-2 (Figure 6C), its inactivated form, 261 phosphorylated Nedd4-2 (Figure 6D,E) and the kinase responsible for its inactivation. 262 serum and glucocorticoid-regulated kinase 1 (SGK1, Figure 6F). The activation of 263 Nedd4-2 was evidenced by a decrease in phosphorylated Nedd4-2 relative to total 264 Nedd4-2 in UBR1 siRNA groups (Figure 6 C-E). Based on these observations, mice 265 were transfected icv with a lentivirus encoding a scrambled or Nedd4-2 shRNA (Figure 266 267 S3 in data supplement). While baseline BP was not affected by the treatment, a blunted hypertension was noted early on post Ang-II infusion. However, this reduction of 268 hypertension did not persist and was gone by the third week of Ang-II treatment. To 269 further understand the mechanism of Nedd4-2 activation, we measured the protein 270 271 expression of SGK1, the kinase responsible for Nedd4-2 phosphorylation. Indeed, SGK1 protein levels were also reduced in UBR1 siRNA treated groups, supporting the 272 273 overall activation of Nedd4-2 in UBR1 knockdown mice (Figure 6F).

274

275 **Discussion**

Although ACE2 was discovered in 2000, it took almost 15 years for the first ACE2 ubiquitination data to be reported.² MDM2 was then identified as the first E3 ligase targeting ACE2¹⁰ and our group recently reported the role of Nedd4-2 in ACE2

²⁷⁹ ubiquitination.³ Using a proteomics discovery approach, followed by a multilayer's ²⁸⁰ validation process, we now report the identification of UBR1 as a the first E3 ligase from ²⁸¹ the N-end rule pathway to ubiquitinate ACE2. Moreover, our data show that UBR1 is ²⁸² differentially expressed during hypertension and regulated in a sex-dependent manner.

283 Our group previously reported that upon Ang-II treatment, ACE2 moves from the cell surface to the lysosomes, followed by degradation in lysosomes, leading to a loss of 284 ACE2 expression and compensatory activity in diseases such as hypertension.² This 285 process involving ubiquitination is dependent on AT₁R, and was also observed in the 286 case of S1 spike protein (component of SARS-CoV-2 envelope)-induced ACE2 287 internalization.⁴ Ang-II activation of E3 ligases has long been recognized, notably for 288 Nedd4-2 and Cullin3.⁷ Expression of ACE2 has also been shown to modulate the levels 289 of E3 ligases, for example Smurf2 which is upregulated in the absence of ACE2.²⁶ The 290 COVID-19 pandemic provided a strong impetus to understand the mechanisms involved 291 in ACE2 post-translational regulation and several new ubiguitases have been 292 suggested,^{1,27} although most of them have not been associated with cardiovascular 293 regulation. The exception is our recent identification of Nedd4-2 as an E3 ligase 294 targeting ACE2 in pre-clinical and clinical hypertension.³ In this study we identified and 295 validated UBR1 as a new E3 ligase targeting ACE2. Additionally, we show a synergistic 296 interaction between Nedd4-2 and UBR1. 297

We observed that experimental and clinical hypertension is associated with an 298 upregulation of the E3 ligase UBR1, notably in males. In addition, although some cell 299 specificity was noted, all major tissues involved in BP regulation (*i.e.* brain, heart and 300 kidney) exhibited a similar sex difference. The role of UBR1 in ACE2 ubiquitination was 301 302 further confirmed in loss of function experiments showing that upon silencing UBR1, Ang-II is no longer able to induce ACE2 internalization and degradation. UBR1 is an E3 303 304 ligase part of the N-end rule pathway, that binds and destabilizes N-terminal residues, such as arginine, lysine, histidine, and bulky hydrophobic residues, promoting 305 306 polyubiguitination and the eventual degradation of the substrate. Although UBR1 was primarily reported to modulate proteasomal degradation,²⁸ it also plays a role in the 307 quality control process, independent of the N-end rule pathway.²⁹ Interestingly, UBR1 308 also modulates proteolysis of the regulators of G-protein signaling, RGS4 and RGS5, 309

and differentially controls G-protein-coupled receptor signaling under normoxic/hypoxic 310 conditions.³⁰ Although mutations of the UBR1 gene have been associated with 311 Johanson-Blizzard syndrome, a rare genetic disorder that affects multiple organs,²⁸ to 312 date, there is little information about UBR1 suggesting it plays a role in cardiovascular 313 314 diseases. Previous work reported that pericytes infected by the Japanese encephalitis virus could lead to a compromised blood-brain barrier mediated via UBR1.³¹ This is 315 316 relevant since experimental models of hypertension with increased Ang-II expression increase blood-brain barrier permeability.³² In addition, ACE2 has also been reported to 317 contribute to blood-brain barrier homeostasis.³³ Although not explored in our study, 318 these observations could support a role for UBR1 in blood brain barrier leakage in 319 320 cardiovascular conditions. Our data show that UBR1 upregulation in hypertension was not restricted to the brain but also apparent in the heart and kidney. Moreover, silencing 321 of UBR1 in endothelial cells not only prevented Ang-II-mediated downregulation of 322 ACE2 but was associated with an up-regulation of ACE2. Therefore, it is conceivable 323 that Ang-II-mediated upregulation of UBR1 in endothelial cells promotes ACE2 324 degradation, which in the brain could contribute to blood-brain barrier dysfunction and 325 the establishment of neurogenic hypertension. Downregulation of ACE2 from 326 endothelial cells in the heart and kidneys could also contribute to cardiovascular 327 disease progression through multiple mechanisms, including impaired endothelial 328 329 function.

Another finding from our study is the major role played by sex hormones on ACE2 330 expression and its ubiquitination partners. Clinical and pre-clinical studies have reported 331 opposite effects of sex hormones on ACE2 activity and expression.^{34–38} In line with our 332 333 observations, ACE2 expression is thought to be lower in females than males in multiple cell types, tissues and species,^{34,35,38} while gonadectomy reverses these findings.³⁷ 334 However, unlike our findings, exposure to testosterone led to increased ACE2 335 expression in pulmonary cells from both males and females while 17β-estradiol 336 downregulated ACE2.^{34,36} Intriguingly, expression levels of fascin-1, an actin bundling 337 protein that protects ACE2 against Ang-II downregulation,³⁹ inversely correlates with 338 estrogen receptor alpha expression,^{40,41} indicating that multiple steps in ACE2 339 internalization and degradation can be modulated by sex hormones. In our study, DHT 340

³⁴¹ upregulated UBR1 expression in SMC but not in endothelial cells, and this was ³⁴² associated with a reduction of ACE2. This sex specificity is further supported by a ³⁴³ previous report showing that UBR1 promotes the degradation of the androgen ³⁴⁴ receptor.⁴² To the best of our knowledge, the present study is the first to show the ³⁴⁵ impact of sex hormones on ACE2 ubiquitination.

346

Our validation experiments in cells clearly show the co-dependence between Ang-II and 347 UBR1, with Ang-II promoting UBR1 upregulation and its inability to induce ACE2 348 downregulation when UBR1 has been silenced. Yet, some key questions remain 349 unanswered. Although our data show a massive upregulation of UBR1 in hypertensive 350 experimental conditions associated with increased Ang-II levels, as well as clinical 351 hypertension, we failed to see a major effect of UBR1 silencing on the development of 352 hypertension. This could be partially explained by the concomitant upregulation of active 353 Nedd4-2 and possibly other pro-hypertensive E3 ligases which could have mitigated the 354 impact of UBR1 knockdown by inducing pro-hypertensive pathways. Although 355 associated with developmental abnormalities and cognitive deficits,⁴³ complete deletion 356 of UBR1 in mice is viable further supporting compensation by other UBR1 homologs, for 357 example UBR2, or other E3 ligases. While knockdown of UBR1 had only a modest 358 impact on hypertension, it was sufficient to restore ACE2 expression in the 359 360 hypothalamus. UBR1 knockdown induced a compensatory positive feedback triggering Nedd4-2 activation which we speculate prevented the reduction of hypertension. A 361 362 similar lack of efficiency was also observed when Nedd4-2 knockdown in the brain was initiated prior to the development of hypertension (Figure S3 in data supplement), where 363 364 a transient drop in BP was observed followed by an increase in BP.

Interestingly, the type of ubiquitination driven by UBR1 is also thought to regulate protein function, and as such, it has been involved in trafficking, activation of signaling pathways, as well as synaptic plasticity of excitatory neurons.^{44,45}

Another unresolved question is the trafficking of ACE2 to the nucleus. Other members of the RAS, notably AT_1R , have previously been identified in the nucleus, which forms the basis for the existence of an intracellular RAS.⁴⁶ To our knowledge, there is no

371 previous report of ACE2 being identified in this organelle and further research is needed

to confirm this observation and determine if it is associated with a regulatory function.

373

In summary, the present study identifies a novel E3 ligase involved in ACE2 374 375 ubiquitination, taking place in various organs in experimental and clinical hypertension and potentially capable of modulating ACE2 compensatory activity during the 376 377 development of cardiovascular diseases. Sex differences were further shown to play a critical role in the expression levels of ACE2 and its ubiquitination. We propose that 378 ACE2 ubiquitination is an important mechanism leading to Ang-II-mediated 379 internalization of this enzyme and the loss of its compensatory activity. Inhibition of 380 UBR1 could be a new therapeutic strategy to prevent ACE2 ubiquitination in 381 hypertension. 382

384 **Novelty and Significance:**

385 What is known?

- ACE2 undergoes Ang-II-induced internalization via AT₁R, followed by
 ubiquitination and lysosomal degradation during hypertension.
- Murine double minute 2 (MDM2) and S-Phase Kinase Associated Protein 2
 (Skp2) and Nedd4-2 are E3 ligases that promote ACE2 ubiquitination.
- Estrogens and testosterone affect the expression and activity of RAS
 components, contributing to sex differences in cardiovascular diseases.
- 392

393 What new information does this article contribute?

- UBR1 is a new E3 ligase involved in ACE2 ubiquitination in hypertension,
 especially in males. The increase in UBR1 in hypertensive conditions is
 differentially regulated by sex hormones.
- Ang-II-mediated ACE2 internalization, ubiquitination and degradation is taking
 place within various tissues, including brain, heart and kidney in mice and is
 clinically relevant to hypertensive conditions, as indicated by reduced ACE2
 levels in cardiac samples from hypertensive patients.
- UBR1 works synergistically with Nedd4-2, another E3 ligase, to regulate ACE2
 and BP levels.
- UBR1 could be a new therapeutic target to preserve ACE2 compensatory activity
 in hypertension.
- This work provides new insights into the regulation of ACE2 and highlights
 pathways that could be targeted for BP regulation.

408 Acknowledgments

The authors would like to thank the Wisconsin Donor Network and Versiti Blood Center

- of Wisconsin organ procurement and Duke University teams for obtaining tissue from
- 411 rejected donor organs.
- 412

413 Authors contributions

M. Elgazzaz, N. Lakkappa, C. Berdasco, X. Yue, F. Mauvais-Jarvis, X. Yue, C.M.
Filipeanu and E. Lazartigues designed experiments. M. Elgazzaz, N. Lakkappa, C.
Berdasco, J.J. Guidry, S. Sriramula, J. Xu, U.P. Mohan, L. Restivo, A. Martinez, A.
Scarborough, X. Yue, and H. Daoud performed the experiments. A.M. Beyer, M.A.
Mendiola and D.E. Bowles contributed de-identified patient samples. M. Elgazzaz, N.
Lakkappa, X. Yue, C.M. Filipeanu and E. Lazartigues wrote the manuscript. All authors
contributed to manuscript revision.

421

422 Sources of Funding

This work was supported in part by research grants from the National Institutes of Health (NIH) HL150592 to EL and CMF, COBRE P30GM106392, the Department of Veterans Affairs BX004294 to EL and the Research Enhancement Program at LSU Health-NO. FMJ was supported by grants from the NIH (DK074970) and the department of Veterans Affairs BX005218.

428

429 Disclosures

430 **None**.

432 Figure Legends



434



435

436 Figure 1: UBR1 is upregulated in hypertension and interacts with ACE2.

(A) Hypothalami collected from sham- or Ang-II-treated C57BI6/J male and female mice 437 were subjected to proteomic analysis using Liquid chromatography-mass spectrometry 438 (LC-MS). (B) Proteomics abundance scores of ubiquitin ligase proteins measured by 439 440 LC-MS in hypertensive and normotensive mice. (C) Ubiquitin ligase system proteins interacting with ACE2 according to The Biological General Repository for Interaction 441 Datasets (BioGRID: https://thebiogrid.org/ last accessed on February 10, 2024), 442 showing ACE2 interacting proteins belonging to the ubiquitin proteasome system. (D) 443 444 Systolic and diastolic BP were recorded in C57BI6/J male (blue) and female (magenta) mice at baseline (solid bars) and four weeks after Ang-II (hatched bars) infusion (n=7-445 8/group) during the active (moon icon and shaded area) and resting phases (sun icon). 446 Data are shown as mean ±SEM. Statistical significance: Two-way analysis of variance 447 (ANOVA): *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 vs. respective controls. 448



449

Figure 2: UBR1 and ACE2 expression are differentially regulated by sex 450 hormones in Ang-II-mediated hypertension. Expression of UBR1 (A-C) and ACE2 451 (E-G) was assessed in the mouse hypothalamus, heart, and kidney (n= 6-8/group) after 452 453 4 weeks of Ang-II infusion and in human cardiac left ventricle samples (D,H). Representative immunoassays for UBR1, ACE2 and GAPDH samples from Caucasian 454 and Black donors (n=6-7/group) (D,H). Data are shown as mean ±SEM. Statistical 455 significance: Two-way analysis of variance (ANOVA): ****P<0.0001, **P<0.01 and 456 ^{*}P<0.05. Abbreviations: NT, normotensive; HT, hypertensive. 457

- 459
- 460
- 461



462

Figure 3: UBR1 contributes to Ang-II mediated ACE2 degradation. Human aortic 463 endothelial cells (HAEC) were pre-treated with control (scramble) or UBR1 siRNA for 6 464 hours before exposure to Ang-II (100 nM) for 4 hours. Capillary Western Blot showing a 465 UBR1 siRNA dose-response increase in UBR1 protein level and decrease in ACE2 466 levels (A). Capillary Western Blot showing a restoration of ACE2 levels following the 467 knockdown of HAEC with UBR1 siRNA (B). GFP-labeled ACE2 (Green) localizes at the 468 469 plasma membrane in control cells and internalizes to the cytoplasm after Ang-II treatment. Texas red-labelled UBR1 is present throughout the cell and colocalizes with 470 ACE2 mostly in the nucleus (DAPI, blue) following Ang-II treatment (C). Data are shown 471 as mean ±SEM (n=3, in triplicate). Statistical significance: One-way analysis of variance 472 473 (ANOVA) followed by Bonferroni test for multiple comparisons, *P<0.05, **P<0.01,***P<0.001, ****P<0.0001 474



476

Figure 4: Sex hormones regulation of UBR1. Protein expression of UBR1 and ACE2 477 in human aortic endothelial cells (A,B) and smooth muscle cells (C,D). Expression was 478 β-actin β-tubulin housekeeping 479 normalized to and proteins. MPP (Methylpiperidinopyrazole): selective estrogen receptor alpha blocker; PHTPP: selective 480 estrogen receptor β antagonist; DHT: dihydrotestosterone; DBDi: DNA binding domain 481 inhibitor. One way ANOVA followed by Bonferroni test for multiple comparisons, 482 *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. N=4-6/group. 483



484

485

Figure 5: UBR1 siRNA Infusion in Hypertensive Mice. Experimental timeline of UBR1 siRNA infusion (**A**). Weekly MAP recording in mice infused with Ang-II combined with ICV or subcutaneous UBR1 siRNA (**B**). Summary data showing the average MAP per week in different groups (**C**). One-way ANOVA. *P<0.05, ****P<0.0001, n=4-15/group.



492

Figure 6: Protein Expression in UBR1 siRNA-Infused Hypertensive Mice. Capillary 493 Western showing protein levels in the hypothalamus for UBR1 (A, ~230 kDa), ACE2 (B, 494 495 ~140 kDa), Nedd4-2 (C, ~130 kDa), pNedd4-2 (D, ~130 kDa), pNedd4-2 to Nedd4-2 ratio (E), and SGK1 (F, ~49 kDa) in various treatment groups. TP: total protein. One-496 497 way analysis of variance (ANOVA) followed by Bonferroni test for multiple comparisons, ****P<0.0001; ***P<0.001; **P<0.001; *P<0.05, n=4-5/group. 498

500

501 **Graphical abstract: Ang-II promotes ACE2 ubiquitination and hypertension.** Ang-II 502 binding to AT₁R is associated with upregulation of the E3 ligases UBR1 and Nedd4-2, 503 mostly in males. UBR1 and enhanced active Nedd4-2 both contribute to ACE2 504 polyubiquitination eventually leading to ACE2 degradation, the loss of compensatory 505 activity and hypertension.

506



508 **References**

- Elgazzaz M, Filipeanu C, Lazartigues E. The 2023 Lewis K. Dahl Memorial Lecture: Angiotensin-Converting Enzyme 2 Posttranslational Modifications-Implications for Hypertension and SARS-CoV-2 Infection. *Hypertens Dallas Tex* 1979. 2024;
- Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II
 Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation
 Through an Angiotensin II Type I Receptor-Dependent Mechanism. *Hypertension*.
 2014;64:1368–1375.
- Mohammed M, Ogunlade B, Elgazzaz M, Berdasco C, Lakkappa N, Ghita I, Guidry
 J. J, Sriramula S, Xu J, Restivo L, Mendiola-Pla MA, Bowles D, Beyer AM, Yue X,
 Lazartigues E, Filipeanu CM. Nedd4-2 upregulation is associated with ACE2
 ubiquitination in hypertension. *Cardiovasc Res.* 2023;119:2130–2141.
- 4. Ogunlade BO, Lazartigues E, Filipeanu CM. Angiotensin Type 1 Receptor Dependent Internalization of SARS-CoV-2 by Angiotensin-Converting Enzyme 2.
 Hypertension. 2021;77:e42–e43.
- 524 5. Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in 525 neuronal function and dysfunction. *Nat Rev Neurosci*. 2008;9:826–38.
- 526 6. Clague MJ, Urbé S. Ubiquitin: same molecule, different degradation pathways. 527 *Cell*. 2010;143:682–5.
- Yamazaki O, Hirohama D, Ishizawa K, Shibata S. Role of the Ubiquitin Proteasome
 System in the Regulation of Blood Pressure: A Review. *Int J Mol Sci.* 2020;21:5358.
- 8. Van Huysse JW, Amin MS, Yang B, Leenen FH. Salt-induced hypertension in a
 mouse model of Liddle syndrome is mediated by epithelial sodium channels in the
 brain. *Hypertension*. 2012;60:691–6.
- Snyder PM, Price MP, McDonald FJ, Adams CM, Volk KA, Zeiher BG, Stokes, Jb,
 Welsh MJ. Mechanism by which Liddle's syndrome mutations increase activity of a
 human epithelial Na+ channel. *Cell*. 1995;83:969–978.
- 537 10. Shen H, Zhang J, Wang C, Jain PP, Xiong M, Shi X, Lei Y, Chen S, Yin Q,
 538 Thistlethwaite PA, Wang J, Gong K, Yuan ZY, Yuan JX, Shyy JY. MDM2-Mediated
 539 Ubiquitination of ACE2 Contributes to the Development of Pulmonary Arterial
 540 Hypertension. *Circulation*. 2020;
- Asmamaw MD, Liu Y, Zheng YC, Shi XJ, Liu HM. Skp2 in the ubiquitin-proteasome
 system: A comprehensive review. *Med Res Rev.* 2020;40:1920–1949.

- 12. Wang G, Zhao Q, Zhang H, Liang F, Zhang C, Wang J, Chen Z, Wu R, Yu H, Sun
 B, Guo H, Feng R, Xu K, Zhou G. Degradation of SARS-CoV-2 receptor ACE2 by
 the E3 ubiquitin ligase Skp2 in lung epithelial cells. *Front Med*. 2021;15:252–263.
- Ji H, Menini S, Zheng W, Pesce C, Wu X, Sandberg K. Role of angiotensin converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal
 pathology in renal wrap hypertension in rats. *Exp Physiol*. 2008;93:648–57.
- Liu J, Ji H, Zheng W, Wu X, Zhu JJ, Arnold AP, Sandberg K. Sex differences in
 renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol dependent and sex chromosome-independent. *Biol Sex Differ*. 2010;1:6.
- 15. Bhatia K, Zimmerman MA, Sullivan JC. Sex differences in angiotensin-converting
 enzyme modulation of Ang (1-7) levels in normotensive WKY rats. *Am J Hypertens*.
 2013;26:591–8.
- 16. Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. *Nat Rev Nephrol.* 2018;14:185–201.
- 17. Medina D, Mehay D, Arnold AC. Sex differences in cardiovascular actions of the renin-angiotensin system. *Clin Auton Res.* 2020;30:393–408.
- Bukowska A, Spiller L, Wolke C, Lendeckel U, Weinert S, Hoffmann J, Bornfleth P,
 Kutschka I, Gardemann A, Isermann B, Goette A. Protective regulation of the
 ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men.
 Exp Biol Med Maywood. 2017;242:1412–1423.
- Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome
 Coronavirus Infection. *J Immunol*. 2017;198:4046–4053.
- Xia H, Sriramula S, Chhabra K, Lazartigues E. Brain ACE2 Shedding Contributes
 to the Development of Neurogenic Hypertension. *Circ Res.* 2013;113:1087–1096.
- Xu J, Sriramula S, Xia H, Moreno-Walton L, Culicchia F, Domenig O, Poglitsch M,
 Lazartigues E. Clinical Relevance and Role of Neuronal AT1 Receptors in
 ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension. *Circ Res.* 2017;121:43–55.
- Wallentin L, Lindbäck J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD,
 Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting
 enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts
 of patients with atrial fibrillation. *Eur Heart J*. 2020;41:4037–4046.
- Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF,
 Rienstra M, Friedrich AW, Samani NJ, Ng LL, Dickstein K, Lang CC, Filippatos G,
 Anker SD, Ponikowski P, Metra M, van Veldhuisen DJ, Voors AA. Circulating
 plasma concentrations of angiotensin-converting enzyme 2 in men and women with

- heart failure and effects of renin-angiotensin-aldosterone inhibitors. *Eur Heart J.*2020;41:1810–1817.
- Yue X, Guidry JJ. Differential Protein Expression Profiles of Bronchoalveolar
 Lavage Fluid Following Lipopolysaccharide-Induced Direct and Indirect Lung Injury
 in Mice. Int J Mol Sci. 2019;20.
- S85 25. Oughtred R, Rust J, Chang C, Breitkreutz B, Stark C, Willems A, Boucher L, Leung
 G, Kolas N, Zhang F, Dolma S, Coulombe-Huntington J, Chatr-aryamontri A,
 Dolinski K, Tyers M. The BioGRID database: A comprehensive biomedical
 resource of curated protein, genetic, and chemical interactions. *Protein Sci Publ Protein Soc.* 2021;30:187–200.
- Liu Z, Huang XR, Chen HY, Fung E, Liu J, Lan HY. Deletion of Angiotensin Converting Enzyme-2 Promotes Hypertensive Nephropathy by Targeting Smad7
 for Ubiquitin Degradation. *Hypertension*. 2017;70:822–830.
- Lazartigues E, Llorens-Cortes C, Danser AHJ. New Approaches Targeting the
 Renin-Angiotensin System: Inhibition of Brain Aminopeptidase A, ACE2
 Ubiquitination, and Angiotensinogen. *Can J Cardiol.* 2023;39:1900–1912.
- 596 28. Kim JG, Shin HC, Seo T, Nawale L, Han G, Kim BY, Kim SJ, Cha-Molstad H.
 597 Signaling Pathways Regulated by UBR Box-Containing E3 Ligases. *Int J Mol Sci.*598 2021;22.
- Nillegoda NB, Theodoraki MA, Mandal AK, Mayo KJ, Ren HY, Sultana R, Wu K,
 Johnson J, Cyr DM, Caplan AJ. Ubr1 and Ubr2 function in a quality control
 pathway for degradation of unfolded cytosolic proteins. *Mol Biol Cell*.
 2010;21:2102–16.
- 30. Lee MJ, Tasaki T, Moroi K, An JY, Kimura S, Davydov IV, Kwon YT. RGS4 and
 RGS5 are in vivo substrates of the N-end rule pathway. *Proc Natl Acad Sci U S A*.
 2005;102:15030–5.
- 606 31. Chen CJ, Ou YC, Li JR, Chang CY, Pan HC, Lai CY, Liao SL, Raung SL, Chang
 607 CJ. Infection of pericytes in vitro by Japanese encephalitis virus disrupts the
 608 integrity of the endothelial barrier. *J Virol.* 2014;88:1150–61.
- Mowry FE, Peaden SC, Stern JE, Biancardi VC. TLR4 and AT1R mediate blood brain barrier disruption, neuroinflammation, and autonomic dysfunction in
 spontaneously hypertensive rats. *Pharmacol Res.* 2021;174:105877.
- 33. DeOre BJ, Tran KA, Andrews AM, Ramirez SH, Galie PA. SARS-CoV-2 Spike
 Protein Disrupts Blood-Brain Barrier Integrity via RhoA Activation. *J Neuroimmune Pharmacol.* 2021;1–7.
- Kalidhindi RSR, Borkar NA, Ambhore NS, Pabelick CM, Prakash YS, Sathish V.
 Sex steroids skew ACE2 expression in human airway: a contributing factor to sex

- differences in COVID-19? *Am J Physiol Lung Cell Mol Physiol*. 2020;319:L843-1847.
- 35. Chen K, Bi J, Su Y, Chappell MC, Rose JC. Sex-Specific Changes in Renal
 Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene
 Expression and Enzyme Activity at Birth and Over the First Year of Life. *Reprod Sci.* 2016;23:200–10.
- Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash YS, Chiarella SE.
 Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated
 airway epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2020;318:L1280-I1281.
- 37. Dalpiaz PL, Lamas AZ, Caliman IF, Ribeiro RF, Abreu GR, Moyses MR, Andrade
 TU, Gouvea SA, Alves MF, Carmona AK, Bissoli NS. Sex Hormones Promote
 Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility
 in Spontaneously Hypertensive Rats. *PLos ONE*. 2015;10:e0127515.
- 38. Pendergrass KD, Pirro NT, Westwood BM, Ferrario CM, Brosnihan KB, Chappell
 MC. Sex differences in circulating and renal angiotensins of hypertensive mRen(2).
 Lewis but not normotensive Lewis rats. *Am J Physiol Heart Circ Physiol.*2008;295:H10-20.
- 39. Ogunlade B, Guidry JJ, Mukerjee S, Sriramula S, Lazartigues E, Filipeanu CM. The
 Actin Bundling Protein Fascin-1 as an ACE2-Accessory Protein. *Cell Mol Neurobiol.* 2020;Online ahead of print:1–9.
- 40. Rezaul K, Thumar JK, Lundgren DH, Eng JK, Claffey KP, Wilson L, Han DK.
 Differential protein expression profiles in estrogen receptor-positive and -negative
 breast cancer tissues using label-free quantitative proteomics. *Genes Cancer*.
 2010;1:251–71.
- 41. Esnakula AK, Ricks-Santi L, Kwagyan J, Kanaan YM, DeWitty RL, Wilson LL, Gold
 B, Frederick WA, Naab TJ. Strong association of fascin expression with triple
 negative breast cancer and basal-like phenotype in African-American women. J *Clin Pathol.* 2014;67:153–60.
- 42. Sultana R, Theodoraki MA, Caplan AJ. Specificity in the actions of the UBR1
 ubiquitin ligase in the degradation of nuclear receptors. *FEBS Open Bio*.
 2013;3:394–397.
- 43. An JY, Seo JW, Tasaki T, Lee MJ, Varshavsky A, Kwon YT. Impaired
 neurogenesis and cardiovascular development in mice lacking the E3 ubiquitin
 ligases UBR1 and UBR2 of the N-end rule pathway. *Proc Natl Acad Sci U S A*.
 2006;103:6212–7.
- 44. Erpapazoglou Z, Walker O, Haguenauer-Tsapis R. Versatile roles of k63-linked
 ubiquitin chains in trafficking. *Cells*. 2014;3:1027–88.

- 45. Kim S, Zhang Y, Jin C, Lee Y, Kim Y, Han K. Emerging roles of Lys63-linked
- 655 polyubiquitination in neuronal excitatory postsynapses. Arch Pharm Res.
- 656 2019;42:285–292.

657